Chargement en cours...
Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myeloma
Aplidin® is an antitumour drug, currently undergoing phase II evaluation in different haematological and solid tumours. In this study, we analysed the antimyeloma effects of Aplidin in the syngeneic 5T33MM model, which is representable for the human disease. In vitro, Aplidin inhibited 5T33MMvv DNA...
Enregistré dans:
| Auteurs principaux: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Nature Publishing Group
2008
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2441967/ https://ncbi.nlm.nih.gov/pubmed/18521088 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604388 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|